Lipid-Lowering Agents and the Risk of Cognitive Impairment That Does Not Meet Criteria for Dementia, in Relation to Apolipoprotein E Status

Lipid-lowering agents (LLAs) might lower the risk of dementia, but any impact on other forms of cognitive impairment is not clear. We examined LLAs in relation to cognitive impairment, no dementia (CIND) and apolipoprotein E4 status. In a case control study from the Canadian Study of Health and Aging, cases (n = 347) had developed CIND between the first and second study waves and controls (n = 693) had no cognitive impairment at either time. LLA use was associated with a lower odds of incident CIND in those <80 years of age (OR 0.37; 95% CI 0.15–0.93) but not for those aged ≧80 years (OR 0.56; 95% CI 0.15–2.10). The reduced risk was significant for statins but not for other LLAs. Adjusting for apolipoprotein E4 status did not change the point estimates of the ORs. The greatest impact of LLAs was seen in the CIND subtype circumscribed memory impairment.

[1]  S. Feasson,et al.  MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial. , 2008 .

[2]  H. Feldman,et al.  Is Mild Cognitive Impairment a Valid Target of Therapy , 2007, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[3]  B. Miller,et al.  Subtype of Mild Cognitive Impairment and Progression to Dementia and Death , 2006, Dementia and Geriatric Cognitive Disorders.

[4]  K. Rockwood,et al.  Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[5]  P. Zandi,et al.  Cholesterol and Alzheimer's disease—is there a relation? , 2006, Mechanisms of Ageing and Development.

[6]  F. Pasquier,et al.  Lipid lowering agents are associated with a slower cognitive decline in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[7]  L. Kuller,et al.  Statins and cognitive function in the elderly , 2005, Neurology.

[8]  J. Fisk,et al.  Outcomes of incident mild cognitive impairment in relation to case definition , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[9]  Lewis H Kuller,et al.  Statin use and the risk of incident dementia: the Cardiovascular Health Study. , 2005, Archives of neurology.

[10]  D. Sparks,et al.  Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD. , 2005, Current Alzheimer Research.

[11]  Patrick Browne,et al.  Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. , 2005, Archives of neurology.

[12]  D. Sparks,et al.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.

[13]  B. Wolozin,et al.  Cholesterol, statins and dementia , 2004, Current opinion in lipidology.

[14]  Richard Mayeux,et al.  Relation of plasma lipids to Alzheimer disease and vascular dementia. , 2004, Archives of neurology.

[15]  G. McGwin,et al.  Association between Statin Use and Alzheimer’s Disease , 2004, Neuroepidemiology.

[16]  H. Tuokko,et al.  Five-year follow-up of cognitive impairment with no dementia. , 2003, Archives of neurology.

[17]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[18]  H. Dodge,et al.  Use of Lipid‐Lowering Drugs in Older Adults With and Without Dementia: A Community‐Based Epidemiological Study , 2002, Journal of the American Geriatrics Society.

[19]  Jan A Staessen,et al.  The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. , 2002, Archives of internal medicine.

[20]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[21]  V. Hirth,et al.  The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. , 2002, The journals of gerontology. Series A, Biological sciences and medical sciences.

[22]  Kenneth Rockwood,et al.  Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. , 2002, Archives of neurology.

[23]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[24]  R. Haley,et al.  Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease? , 2000, Archives of neurology.

[25]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[26]  The incidence of dementia in Canada , 2000, Neurology.

[27]  K. Rockwood,et al.  Spectrum of Disease in Vascular Cognitive Impairment , 1999, Neuroepidemiology.

[28]  Janice E Graham,et al.  Prevalence and severity of cognitive impairment with and without dementia in an elderly population , 1997, The Lancet.

[29]  D. Hogan,et al.  Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. , 1995, Archives of neurology.

[30]  H. Chui,et al.  The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.

[31]  Combination Pharmacotherapy.  Combination Pharmacotherapy for Cardiovascular Disease , 2005, Annals of Internal Medicine.

[32]  K. Rockwood,et al.  Differential effects of lipid-lowering agents on human cholinesterases. , 2004, Clinical biochemistry.

[33]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[34]  B. L. Beattie,et al.  Standardization of the diagnosis of dementia in the Canadian Study of Health and Aging. , 1996, Neuroepidemiology.

[35]  Canadian study of health and aging: study methods and prevalence of dementia. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[36]  浜田賀代子,et al.  老年期痴呆患者のスクリーニングにおけるThe modified mini-mental state (3MS) examination日本語版の有用性 , 1992 .

[37]  T. Crook,et al.  Age-associated memory impairment: diagnostic criteria and treatment strategies. , 1988, Psychopharmacology bulletin.